Main problems of gene technology

Compared with foreign countries, there is indeed a big gap in the basic research of molecular biology in China, and there is a big institutional defect in the industrialization of scientific research results. First of all, in terms of investment and financing system, China has not yet established a mature investment and financing system suitable for the era of knowledge economy, such as venture capital fund, national high-tech industry investment fund, and OTC securities trading market for small and medium-sized enterprises. Therefore, many scientific research achievements have a bottleneck effect in the process of transforming into productive forces. Because of the research and development of a genetically engineered drug, its investment is often more than ten times that of general drugs. Many manufacturers have studied products, because the initial investment is huge, and the follow-up funds can't keep up, which leads to the process stopping. Therefore, the serious shortage of funds has been puzzling the upstream, middle and downstream development of bioengineering products.

With the approach of GATT, which successfully negotiated intellectual property rights between China and the United States, genetically engineered drugs, like other drugs, also have a very serious form, that is, patent infringement. According to the opinions of China and the United States, the patents before 1986 can be copied in China, and the patents after 1986 have patent infringement problems. Before 1986, only genetically engineered drugs, such as human insulin, human growth hormone, interferon α and γ, interleukin -2, were approved, and the rest were "patent infringement" products after 1986. Domestic researchers are also actively working to bypass the obstacles of "patent", such as the success of EPO.

China's new product approval management regulations and procedures still need to be further improved, and the expert team for new product review also needs to be updated. The technical level, academic level and practical experience of professional reviewers should be improved, otherwise it will affect the market development speed of new drugs, waste funds and affect the development of national industries.